As of June 30, 2026, Bluejay Diagnostics, Inc. carries a market capitalization of 4.97M, placing it among publicly traded companies globally. Its enterprise value stands at -4.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.97M |
| Enterprise Value | -4.56M |
Bluejay Diagnostics, Inc.'s next confirmed earnings release is scheduled for March 23, 2027.
| Earnings Date | 3/23/2027 |
As of June 30, 2026, Bluejay Diagnostics, Inc. has 1.03M shares outstanding.
| Shares Outstanding | 1.03M |
These figures are as of June 30, 2026.
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | -0.69 |
| P/OCF Ratio | -0.73 |
As of June 30, 2026, Bluejay Diagnostics, Inc. maintains a current ratio of 4.64, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.78, indicating moderate leverage, while an interest coverage ratio of -18,569.15 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.64 |
| Quick Ratio | 4.53 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -18,569.15 |
Over the twelve months ended June 30, 2026, Bluejay Diagnostics, Inc. posted a negative return on equity (ROE) of -98.89, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -81.07, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 6.25, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -98.89 |
| Return on Assets (ROA) | -81.07 |
| Employee Count | 6.25 |
As of the close on November 16, 2026, Bluejay Diagnostics, Inc.'s stock has declined approximately 90.33% over the past 52 weeks. The 50-day moving average sits at 3.05, while the 200-day moving average is 6.83.
| 52-Week Price Change | -90.33% |
| 50-Day Moving Average | 3.05 |
| 200-Day Moving Average | 6.83 |
Over the twelve months ended June 30, 2026, Bluejay Diagnostics, Inc. generated - - in revenue and converted that into -7.27M in net income, yielding earnings per share of -8.06. EBITDA reached -7.19M, while operating income came in at -7.37M.
| Operating Income | -7.37M |
| Pretax Income | -7.27M |
| Net Income | -7.27M |
| EBITDA | -7.19M |
| EBIT | -7.37M |
| Earnings Per Share (EPS) | -8.06 |
As of June 30, 2026, Bluejay Diagnostics, Inc. holds 9.60M in cash and equivalents against 73,444.00 in total debt, resulting in a net debt position of -9.60M. Total book value stands at 9.41M, with working capital of 7.70M providing operational flexibility.
| Cash & Cash Equivalents | 9.60M |
| Total Debt | 73,444.00 |
| Net Debt | -9.60M |
| Equity (Book Value) | 9.41M |
| Book Value Per Share | 9.10 |
| Working Capital | 7.70M |
Bluejay Diagnostics, Inc. produced -5.90M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -335,497.00 in capital expenditures, free cash flow totaled -6.24M - equivalent to -6.92 per share.
| Operating Cash Flow | -5.90M |
| Capital Expenditures | -335,497.00 |
| Free Cash Flow | -6.24M |
| FCF Per Share | -6.92 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -144.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -229.35, meaning Bluejay Diagnostics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -229.35 |
| FCF Yield | -144.07 |
Bluejay Diagnostics, Inc.'s most recent stock split took place on November 3, 2026 with a 4:1 split ratio.
| Last Split Date | 11/3/2026 |
| Split Ratio | 4:1 |
As of June 30, 2026, Bluejay Diagnostics, Inc. has an Altman Z-Score of -5.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.45 |